Valencia M, Medina R, Calixto E, Rodriguez N
Neuropsychiatr Dis Treat. 2022; 18:2069-2082.
PMID: 36133029
PMC: 9484561.
DOI: 10.2147/NDT.S370449.
Miron A, Teodorescu A, Ifteni P, Irimie C, Dima L, Petric P
Psychiatr Q. 2022; 93(2):627-635.
PMID: 35235126
PMC: 8888267.
DOI: 10.1007/s11126-021-09924-9.
Dockendorf M, Hansen B, Bateman K, Moyer M, Shah J, Shipley L
Clin Transl Sci. 2020; 14(2):445-459.
PMID: 33048475
PMC: 7993267.
DOI: 10.1111/cts.12910.
Ersan E
Community Ment Health J. 2019; 56(3):498-505.
PMID: 31734764
DOI: 10.1007/s10597-019-00506-5.
Madera J, Such P, Zhao C, Baker R
Neuropsychiatr Dis Treat. 2019; 15:1593-1604.
PMID: 31354275
PMC: 6590622.
DOI: 10.2147/NDT.S198786.
Predictors of medication adherence among patients with severe psychiatric disorders: findings from the baseline assessment of a randomized controlled trial (Tecla).
Stentzel U, Berg N, Schulze L, Schwaneberg T, Radicke F, Langosch J
BMC Psychiatry. 2018; 18(1):155.
PMID: 29843676
PMC: 5975380.
DOI: 10.1186/s12888-018-1737-4.
Does Non-Adherence Increase Treatment Costs in Schizophrenia?.
Pennington M, McCrone P
Pharmacoeconomics. 2018; 36(8):941-955.
PMID: 29700755
DOI: 10.1007/s40273-018-0652-3.
When all else fails: supervised treatment in outpatient for schizophrenia (STOPS).
Tan H
BMJ Case Rep. 2017; 2017.
PMID: 28942410
PMC: 5747828.
DOI: 10.1136/bcr-2017-221518.
The effect of switching from oral low-dose aripiprazole to aripiprazole once-monthly 300 mg on the quality of life in three patients with schizophrenia.
Suzuki H, Hibino H, Inoue Y, Matsumoto H, Mikami K
SAGE Open Med Case Rep. 2017; 5:2050313X17710594.
PMID: 28596830
PMC: 5448866.
DOI: 10.1177/2050313X17710594.
Efficacy, tolerability, and safety of aripiprazole once-monthly versus other long-acting injectable antipsychotic therapies in the maintenance treatment of schizophrenia: a mixed treatment comparison of double-blind randomized clinical trials.
Majer I, Gaughran F, Sapin C, Beillat M, Treur M
J Mark Access Health Policy. 2016; 3.
PMID: 27123183
PMC: 4802697.
DOI: 10.3402/jmahp.v3.27208.
Once-monthly paliperidone palmitate in recently diagnosed and chronic non-acute patients with schizophrenia.
Hargarter L, Bergmans P, Cherubin P, Keim S, Conca A, Serrano-Blanco A
Expert Opin Pharmacother. 2016; 17(8):1043-53.
PMID: 27042990
PMC: 4898156.
DOI: 10.1080/14656566.2016.1174692.
A Flexible-Dose Study of Paliperidone ER in Patients With Nonacute Schizophrenia Previously Treated Unsuccessfully With Oral Olanzapine.
Kotler M, Dilbaz N, Rosa F, Paterakis P, Milanova V, Smulevich A
J Psychiatr Pract. 2016; 22(1):9-21.
PMID: 26813484
PMC: 4770270.
DOI: 10.1097/PRA.0000000000000117.
Tecla: a telephone- and text-message based telemedical concept for patients with severe mental health disorders--study protocol for a controlled, randomized, study.
Stentzel U, Grabe H, Strobel L, Penndorf P, Langosch J, Freyberger H
BMC Psychiatry. 2015; 15:273.
PMID: 26537570
PMC: 4634903.
DOI: 10.1186/s12888-015-0659-7.
Aripiprazole (ABILIFY MAINTENA®): a review of its use as maintenance treatment for adult patients with schizophrenia.
Shirley M, Perry C
Drugs. 2014; 74(10):1097-110.
PMID: 24969315
DOI: 10.1007/s40265-014-0231-7.
Long-term safety and efficacy of olanzapine long-acting injection in patients with schizophrenia or schizoaffective disorder: a 6-year, multinational, single-arm, open-label study.
McDonnell D, Landry J, Detke H
Int Clin Psychopharmacol. 2014; 29(6):322-31.
PMID: 24850228
PMC: 4186735.
DOI: 10.1097/YIC.0000000000000038.
Medication adherence in schizophrenia.
Acosta F, Hernandez J, Pereira J, Herrera J, Rodriguez C
World J Psychiatry. 2013; 2(5):74-82.
PMID: 24175171
PMC: 3782179.
DOI: 10.5498/wjp.v2.i5.74.
Long-term remission in schizophrenia and schizoaffective disorder: results from the risperidone long-acting injectable versus quetiapine relapse prevention trial (ConstaTRE).
Smeraldi E, Cavallaro R, Folnegovic-Smalc V, Bidzan L, Ceylan M, Schreiner A
Ther Adv Psychopharmacol. 2013; 3(4):191-9.
PMID: 24167692
PMC: 3805434.
DOI: 10.1177/2045125313479127.
Psychiatrists' awareness of partial and nonadherence to antipsychotic medication in schizophrenia: results from an Asia-Pacific survey.
Olivares J, Thirunavukarasu M, Kulkarni J, Zhang H, Zhang M, Zhang F
Neuropsychiatr Dis Treat. 2013; 9:1163-70.
PMID: 23976858
PMC: 3747021.
DOI: 10.2147/NDT.S49080.
Psychiatrists' awareness of adherence to antipsychotic medication in patients with schizophrenia: results from a survey conducted across Europe, the Middle East, and Africa.
Olivares J, Alptekin K, Azorin J, Canas F, Dubois V, Emsley R
Patient Prefer Adherence. 2013; 7:121-32.
PMID: 23390361
PMC: 3564476.
DOI: 10.2147/PPA.S37534.
Improving treatment adherence in your patients with schizophrenia: the STAY initiative.
Canas F, Alptekin K, Azorin J, Dubois V, Emsley R, Garcia A
Clin Drug Investig. 2013; 33(2):97-107.
PMID: 23288695
DOI: 10.1007/s40261-012-0047-8.